1. Graybill JR. The echinocandins, first novel class of antifungals in two decades: Will they live up to their promise? Int J Clin Pract 2001;55(9):633–638.

2. Vazquez JA, Lynch M, Boikov D y cols. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997;41(7):1612–1614.

3. Pfaller MA, Marco F, Messer SA y cols. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998;30:251–255.

4. Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient. Oncology 2001;15(3):351–364.

5. Garber G. An overview of fungal infections. Drugs 2001;61(suppl 1):1–12.